StockData
Cooper Companies, Inc. logo

Cooper Companies, Inc.

COONasdaqOphthalmic GoodsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 16/3040% below fair value
$60.33−0.42 (-0.69%)

Close on Nov 19, 2026Market cap $11.47BP/E 20.6Yield –

Cooper Companies CooperVision Sponsored Studies Started by Year

Periods

Cooper Companies CooperVision Sponsored Studies Started: 6 in FY2026, down 14.3% from a year earlier. That is the lowest of the 10 years on record here.

Latest, FY2026
6
Period ended Oct 31, 2026 (CY2026)
Change on a year earlier
-14.3%
7 in FY2025
History
10 years
Since FY2017
Sources
1
U.S. National Library of Medicine — ClinicalTrials.gov Registry

Where the FY2026 figure comes from

Source: U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Cooper Companies CooperVision Sponsored Studies Started, annual FY2017–FY2026 [Data set]. Compiled from Cooper Companies SEC filings and investor materials. https://stockdatahq.com/stocks/coo/kpis/ct-cvi-studies-started

See every metric in the Cooper Companies KPI table. Data updated Nov 18, 2026.

See a number that looks wrong?